Advanced search
Publication Cover
Hematology Volume 26, 2021 - Issue 1
Submit an article Journal homepage
3,144
Views
1
CrossRef citations to date
0
Altmetric
Articles

Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic ITP in routine clinical practice in central and Eastern Europe: an analysis of the PLATON study

Barbara Skopeca Department of Hematology, University Medical Center Ljubljana, Ljubljana, Slovenia;b Medical Faculty, University of Ljubljana, Ljubljana, SloveniaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8836-0091View further author information
ORCID Icon,
Zuzana Sninskac Department of Hematology and Blood Transfusion, University Hospital St. Cyril and Metod, Bratislava, SlovakiaView further author information
,
Nikolai Tzvetkovd Clinic of Hematology, University Multiprofile Hospital for Active Treatment “Dr. Georgi Stranski” EAD, Pleven, BulgariaORCID Iconhttps://orcid.org/0000-0002-8145-6135View further author information
ORCID Icon,
Vladlen Ivanushkine Department of Biostatistics, Quartesian, Kharkov, UkraineView further author information
,
Katja Björklöff Medical Affairs, Amgen (Europe North East), Rotkreuz, SwitzerlandORCID Iconhttps://orcid.org/0000-0002-7678-5938View further author information
ORCID Icon,
Jane Hippenmeyerg Medical Affairs, Amgen (Europe) GmbH, Rotkreuz, SwitzerlandORCID Iconhttps://orcid.org/0000-0002-5480-8916View further author information
ORCID Icon &
Georgi Mihaylovh Clinic of Hematology, Specialized Hospital for Active Treatment of Hematology Diseases AD, Sofia, BulgariaORCID Iconhttps://orcid.org/0000-0002-8435-2825View further author information
ORCID Icon show all
Pages 497-502 | Published online: 08 Jul 2021

References

  • Matzdorff A, Meyer O, Ostermann H, et al. Immune thrombocytopenia – current diagnostics and therapy: recommendations of a Joint Working Group of DGHO, OGHO, SGH, GPOH, and DGTI. Oncol Res Treat. 2018;41(Suppl 5):1–30.
  • Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393.
  • Abrahamson PE, Hall SA, Feudjo-Tepie M, et al. The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review. Eur J Haematol. 2009;83(2):83–89.
  • Terrell DR, Beebe LA, Vesely SK, et al. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol. 2010;85(3):174–180.
  • Grimaldi-Bensouda L, Nordon C, Michel M, et al. Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome. Haematologica. 2016;101(9):1039–1045.
  • Neunert C, Noroozi N, Norman G, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemostasis. 2015;13(3):457–464.
  • Nørgaard M, Cetin K, Mægbæk ML, et al. Risk of arterial thrombotic and venous thromboembolic events in patients with primary chronic immune thrombocytopenia: a Scandinavian population-based cohort study. Br J Haematol. 2016;174(4):639–642.
  • Yusuf HR, Hooper WC, Grosse SD, et al. Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees. Thromb Res. 2015;135(1):50–57.
  • Sestøl HG, Trangbæk SM, Bussel JB, et al. Health-related quality of life in adult primary immune thrombocytopenia. Expert Rev Hematol. 2018;11(12):975–985.
  • Hill QA, Newland AC. Fatigue in immune thrombocytopenia. Br J Haematol. 2015;170(2):141–149.
  • Terrell DR, Reese J, Branesky D, et al. Depression in adult patients with primary immune thrombocytopenia. Am J Hematol. 2016;91(10):E462–E463.
  • Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866.
  • Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–3817.
  • Kashiwagi H, Kuwana M, Hato T, et al. Reference guide for management of adult immune thrombocytopenia in Japan: 2019 revision. Int J Hematol. 2020;111(3):329–351.
  • European Medicines Agency. Nplate® (romiplostim) – summary of product characteristics: European Medicines Agency; 2021. Available from: https://ec.europa.eu/health/documents/community-register/2021/20210122150420/anx_150420_en.pdf.
  • United States Food and Drug Administration. Nplate® (romiplostim) – Product label: United States Food and Drug Administration; 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125268s169lbl.pdf.
  • Kuter DJ, Newland A, Chong BH, et al. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. Br J Haematol. 2019;185(3):503–513.
  • Snell Taylor S, Nielson C, Breskin A, et al. Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic immune thrombocytopenia in European clinical practice. Adv Ther. 2021;38:2672–2688.
  • Mihaylov G, Skopec B, Sninska Z, et al. PLATON: use of romiplostim to treat chronic primary immune thrombocytopenia. Memo. 2020;13(2):227–234.
  • Reiser M, Welslau M, Josten K, et al. Final results from an observational study (PLATEAU) of adult patients treated with romiplostim for primary immune thrombocytopenia (ITP) in routine clinical practice in Germany. Haematologica. 2017;102(s2):591–592.
  • Lozano ML, Godeau B, Grainger J, et al. Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia. Expert Rev Hematol. 2020;13(12):1319–1332.
  • Newland A, Godeau B, Priego V, et al. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. Br J Haematol. 2016;172(2):262–273.
  • Steurer M, Quittet P, Papadaki HA, et al. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice. Eur J Haematol. 2017;98(2):112–120.
  • Greenland S. Randomization, statistics, and causal inference. Epidemiology. 1990;1(6):421–429.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.